Table of Contents

Research Articles

• Research Articles

  Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy

  Esther P.M. Tjin, Gabrielle Krebbers, Kimberley J. Meijlink, Willeke van de Kasteele, Efraim H. Rosenberg, Joyce Sanders, Petra M. Nederlof, Bart A. van de Wiel, John B.A.G. Haanen, Cornelis J.M. Melief, Florry A. Vyth-Dreese and Rosalie M. Luiten

  Cancer Immunol Res June 1 2014 2 (6) 538-546; DOI:10.1158/2326-6066.CIR-13-0097

  
  

  Tjin and colleagues analyzed a large panel of immune markers in patients with stage IV advanced melanoma prior to autologous tumor-cell vaccination and report that high density of intratumoral CD4⁺ and CD8⁺ T cells with elevated granzyme B expression is correlated with favorable clinical outcome.
• Research Articles

  Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma

  Eleanor M. Tyler, Achim A. Jungbluth, Sacha Gnjatic, Richard J. O'Reilly and Guenther Koehne

  Cancer Immunol Res June 1 2014 2 (6) 547-558; DOI:10.1158/2326-6066.CIR-13-0174

  
  

  Tyler and colleagues show that cancer–testis antigen 7 (CT7) protein expression in the bone marrow and CT7-specific T-cell responses in blood are associated with the disease course of patients with multiple myeloma following allogeneic stem cell transplantation, supporting immunotherapeutic targeting of CT7 as a treatment for multiple myeloma.
• Research Articles

  The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo

  Teresa Hemmerle and Dario Neri

  Cancer Immunol Res June 1 2014 2 (6) 559-567; DOI:10.1158/2326-6066.CIR-13-0182

  
  

  Hemmerle and Neri show in three syngeneic murine tumor models that immunocytokine F8–IFNγ targets tumoral fibronectin, recruits and activates leukocytes, and needs relatively high doses to localize on tumors, and that its antitumor activity is potentiated by combination with F8-IL4 without additional toxicities.
• Research Articles

  TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

  Megumi Narusawa, Hiroyuki Inoue, Chika Sakamoto, Yumiko Matsumura, Atsushi Takahashi, Tomoko Inoue, Ayumi Watanabe, Shohei Miyamoto, Yoshie Miura, Yasuki Hijikata, Yoshihiro Tanaka, Makoto Inoue, Koichi Takayama, Toshihiko Okazaki, Mamoru Hasegawa, Yoichi Nakanishi and Kenzaburo Tani

  Cancer Immunol Res June 1 2014 2 (6) 568-580; DOI:10.1158/2326-6066.CIR-13-0143

  
  

  Narusawa and colleagues found that type 1 IFNs and plasmacytoid dendritic cells in the tumor-draining lymph nodes mediate GM-CSF–induced antitumor immunity in immunocompetent mice, and they report that the synthetic TLR7 ligand imiquimod could overcome tolerance and enhance autologous GM-CSF antitumor effects.
• Research Articles

  Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model

  Chiao-Jung Kao, Gregory T. Wurz, Arta M. Monjazeb, Daniel P. Vang, Timothy B. Cadman, Stephen M. Griffey, Michael Wolf and Michael W. DeGregorio

  Cancer Immunol Res June 1 2014 2 (6) 581-589; DOI:10.1158/2326-6066.CIR-13-0205

  
  

  Kao and colleagues report that concurrent cisplatin/tecemotide therapy induced additive reduction in lung tumor foci associated with a Th1 immune response. They further suggest that localized lung radiotherapy may enhance the CTL-driven antitumor activity of tecemotide.